Table 2.

Effect of definitive therapy and baseline characteristics on time to mCRPC and OS.

Variable	Univariate				Multivariate
	CRPC		OS		CRPC		OS
	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value
Age at initiation of ADT, continuous	0.99 (0.98–1.01)	0.55	1.06 (1.03–1.08)	<0.0001	0.99 (0.98–1.01)	0.55	1.05 (1.02–1.08)	0.0011
Race (Black/African American vs. other)	1.02 (0.62–1.60)	0.38	1.62 (0.87–2.86)	0.13	0.58 (0.32–0.99)	0.084	0.87 (0.42–1.72)	0.78
ECOG
0	ref	0.015	ref	<0.0001	ref	0.045	ref	0.012
1	1.31 (0.90–1.88)		2.11 (0.122–3.59)		1.19 (0.76–1.83)		1.42 (0.75–2.64)
2	3.02 (1.26–6.12)		10.03 (3.33–24.71)		2.81 (1.11–6.17)		6.62 (1.87–20.12)
3	15.72 (0.86–79.06)		30.96 (1.66–170.68)		18.01 (0.91–116.63)		23.53 (0.98–259.14)
Gleason score
5	ref	0.017	ref	0.38	ref	0.021	ref	0.63
6	6.61 (0.80–54.55)		3.77 (0.43–32.96)		6.66 (0.78–56.55)		2.70 (0.29–25.28)
7	6.80 (092–49.95)		3.16 (0.41–24.30)		7.65 (1.02–57.41)		3.75 (0.46–30.41)
8	7.71 (1.05–56.97)		4.61 (0.60–35.31)		7.65 (1.00–58.39)		3.62 (0.44–29.75)
9	9.36 (1.27–68.84)		4.94 (0.65–37.53)		9.04 (1.20–68.41)		3.99 (0.50–31.81)
10	17.42 (2.00–151.44)		3.46 (0.21–56.71)		25.07 (2.72–231.26)		10.26 (0.56–187.26)
PSA at initiation of ADT (log, continuous)	1.51 (1.23–1.83)	<0.0001	1.50 (1.13–1.97)	0.0044	1.40 (1.11–1.77)	0.0045	1.11 (0.80–1.54)	0.52
Definitive Treatment (Y vs. N)	0.56 (0.40–0.78)	0.0007	0.47 (0.28–0.77)	0.0029	0.68 (0.45–1.02)	0.063	0.57 (0.28–1.13)	0.11

ADT = androgen deprivation therapy; CI = confidence interval; CRPC = castration-resistant prostate cancer; HR = hazard ratio; OS = overall survival.